Dyadic International, Inc. announced the appointment of Michael Tarnok to the company's Board of Directors. Mr. Tarnok will also serve on the company's audit and compensation committees. Mr. Tarnok has extensive experience in the pharmaceutical industry across many key areas including finance, operations and marketing.

He is the current Chairman and former Interim CEO of Keryx Biopharmaceuticals, Inc., a biotechnology company focused on the development of therapeutics for renal disease. Prior to joining Keryx in 2007, Mr. Tarnok spent the majority of his career at Pfizer Inc., joining in 1989 as Director of Finance for U.S. Manufacturing. From 2000-2007, he served as Senior Vice President in Pfizer's U.S. Pharmaceuticals Division.

Prior to joining Pfizer, he worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation, and Olivetti Corporation of America. Mr. Tarnok earned an MBA in marketing from New York University and a Bachelors of Science in accounting from St. John's University.

He also serves on the Board of the Global Health Counsel, a Washington, D.C.-based NGO.